Beyond KRAS: A new approach in metastatic colorectal cancer

The Lancet Oncology

Volumn 11, Issue 8, 2010, Pages 706-707

  Winder, Thomas ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIREGULIN; IRINOTECAN; K RAS PROTEIN; MESSENGER RNA; OXALIPLATIN; PANITUMUMAB;

CANCER SURVIVAL; CLINICAL TRIAL; CODON; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; GENE DOSAGE; GENE MUTATION; HUMAN; METASTASIS POTENTIAL; MOLECULAR INTERACTION; NOTE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 77955273491     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70147-9     Document Type: Note

References (6)

1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
2. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
3. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, published online July 8. 10.1016/S1470-2045(10)70130-3.
4. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
5. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. 2010 Gastrointestinal Cancers Symposium; Jan 22-24, 2010, Orlando, FL, USA: Abstr 281.
6. Hu YP, Patil SB, Panasiewicz M, et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res 2008, 68:8004-8013.